2015年阿尔茨海默病协会国际会议

2015-07-27 佚名 美通社

--- 药物疗法的临床试验数据结果带来新希望--- 早年生活的风险因素- 1型糖尿病和学校分数--- 对婴儿潮一代的影响-人数多、代价大--- 女性特殊的认知能力风险2015年阿尔茨海默病协会国际会议(Alzheimer's Association International Conference 2015,简称:AAIC 2015)报告了令人激动的新研究成果,涉及多个阿尔茨海默病及痴呆症的研

--- 药物疗法的临床试验数据结果带来新希望

--- 早年生活的风险因素- 1型糖尿病和学校分数

--- 对婴儿潮一代的影响-人数多、代价大

--- 女性特殊的认知能力风险

2015年阿尔茨海默病协会国际会议(Alzheimer's Association International Conference 2015,简称:AAIC 2015)报告了令人激动的新研究成果,涉及多个阿尔茨海默病及痴呆症的研究。相关数据显示了各种与治疗相关的新发现、早期察觉方面的进展、年轻人当中存在的风险因素以及阿尔茨海默病对婴儿潮一代的影响。

2015年阿尔茨海默病协会国际会议(简称:AAIC 2015)报告了令人激动的新研究成果,涉及多个阿尔茨海默病及痴呆症的研究。相关数据显示了各种与治疗相关的新发现、早期察觉方面的进展、年轻人当中存在的风险因素以及阿尔茨海默病对婴儿潮一代的影响。

AAIC 2015上同时重点报告的研究结果还有:阿尔茨海默病对女性的影响比例较大、体育锻炼对阿尔茨海默病和其它痴呆症的有益影响。

AAIC 是报告和讨论最新的阿尔茨海默病和痴呆症研究的最重要的年度论坛。AAIC 2015让世人能更快地了解痴呆症科学研究方面的突破性发现,共有来自世界各地约70个国家的4,500名左右的专家和研究者汇聚一堂聆听2200多场科学报告。

新的数据结果显示治疗阿尔茨海默病有新希望

在 AAIC 上披露的十几种试验性药物的研究结果表明研究团队从多个角度试图治疗阿尔茨海默病、以根本原因和一些最致命的症状为治疗目标。这些进步显示阿尔茨海默病的研究已经成熟、承认需要进行更广泛的治疗,并且暗示未来可能会出现联合治疗方法。新报告包括三种以反常淀粉样蛋白(在大脑中形成神经斑,这是阿尔茨海默病的标志之一)为靶向的药物的高级试验和新的分析,加上三种以其它该疾病的路径和症状(包括躁动这类精神症状)为靶向的药物试验。

根据在动物模型和试管上进行的小规模初步研究,从长远来看,在 AAIC 2015上披露的另一类研究的早期结果显示有三类试验性药物可能可以对引起痴呆症(包括阿尔茨海默病、帕金森氏综合症和路易体痴呆症)的大脑疾病起作用。

2800万婴儿潮一代将患上阿尔茨海默病

在 AAIC 2015上,The Lewin Group 受阿尔茨海默病协会之托进行的预测报告显示到本世纪中叶将有2800万婴儿潮一代患上阿尔茨海默病。除非在治疗和预防上有重大的进步,否则这种大规模爆发的疾病到2040年将会花去25%的医疗保险(Medicare)支出。今年早些时候 The Lewin Group 的一份研究表示一种能将阿尔茨海默病发作时间推迟5年的治疗方法在它推出的最初几年内能节省2200亿美元的开支。

1型糖尿病被认定为是患上阿尔茨海默病的一个风险因素

AAIC 2015上还公布了首个关于患有1型糖尿病的年纪较大的人群患上包括阿尔茨海默病在内的痴呆症可能性的研究。在查看了490,000多位年过60的人的健康数据资料库后该研究发现--患有1型糖尿病的人就算糖尿病已经治愈与没有糖尿病的人想比患上痴呆症的可能性要高出60%至93%。需要更多的研究才能证实这一调查结果和查明患有1型糖尿病的人风险更大的生理原因。1型糖尿病和2型糖尿病患者的人数在全球范围内快速增加,并且患有1型糖尿病的人存活期与之前相比更长。

早期的教育对未来是否会患上阿尔茨海默病有影响

在 AAIC 2015上,瑞典的两项研究表明儿童时期(9-10岁)的学校表现与后期出现痴呆症有相关性。两项研究分析了早期教育、中等教育和职业复杂性对发生痴呆症的影响。第一项研究对75000多位年纪在65岁及以上的人进行了调查,调查发现童年时期学校成绩处于最差的20%的那些人患上痴呆症的可能性要高出21%,而如果职业复杂性较高(涉及数据和数字时)患痴呆症的可能性降低23%。值得注意的是,较高的职业复杂性并不能弥补儿童时期较低的学校成绩的影响。第二项研究结果也发现分数/职业复杂性与患痴呆的可能性有很大的相关性。这项研究对年纪在75岁或以上的440名男性和女性进行了调查,发现就算他们接受了更正规的教育或较复杂的工作,如果他们的早年学校分数处于最低的20%的人当中,75岁以上的人患痴呆症的可能性提高了50%。根据阿尔茨海默病协会《爱上大脑的10种方法》(10 Ways to Love Your Brain)所述,任何阶段的正规教育将有助于降低认知能力下降和患痴呆的可能性。

女性在认知能力下降和患痴呆症方面风险更大

女性受到阿尔茨海默病影响的人数较多。根据阿尔茨海默病协会《2015年阿尔茨海默病情况及数据》(2015 Alzheimer's Disease Facts and Figures)所述,在患有阿尔茨海默病的美国老年人当中约有三分之二的人是女性。女性也极有可能是阿尔茨海默病患者的护理者。最近的数据显示所有无报酬的阿尔茨海默病和痴呆症护理者当中有63%是女性。

在 AAIC 2015上,有两项研究揭示了两性在阿尔茨海默病和认知能力下降的速度和影响上存在差异。在一项对患有轻度认知障碍的400人(绝大部分为70多岁,其中141位女性,257位男性)的研究表明,在认知和活动能力上女性的衰退速度要比男性快一倍。此外,在大会上报告的另外一项研究结果(从两个考察认知老化的不同项目的数据库中抽取了527位老人的数据)显示,在进行过全身麻醉的外科手术之后,女性在认知、活动能力和大脑大小方面与男性相比下降幅度非常大。很显然现在需要调查出现这种情况的原因。是不是仅仅因为女性寿命更长,或是因为解剖学、生物学和/或遗传学上的某些不同导致患病更普遍或能力下降更快?

研究者透露预测阿尔茨海默病发展的新方法

AAIC 2015上的研究报告显示,大脑扫描、记忆力测试和津液可能是了解一个人患阿尔茨海默病可能性的关键所在,即便是在那些不存在与该病有关的记忆力和思维问题的人当中也是如此。特别有趣的是,有一项小规模的研究表明将来有一天可能可以通过唾液测出阿尔茨海默病这类疾病的变化。唾液采集方便、易于运输、已经被成功地应用于各种疾病的诊断。另一项研究表明正电子成像术(PET) 脑部炎症扫描将来可能会用于检查此病和跟踪治疗情况。

体育锻炼可能是阿尔茨海默病和血管性痴呆症的一种有效的治疗方法

我们知道有规律的体育活动可能会降低认知能力下降、阿尔茨海默病和其它痴呆症的风险。在 AAIC 2015上,有三项新研究报告显示中等强度或高强度的有氧运动对阿尔茨海默病和其它痴呆症患者的价值--这类运动可以让患者活得更好。一项对200名年纪在50-90岁的阿尔茨海默病患者的研究表明,研究参与者在完成为期4个月的高强度有氧运动后焦虑、易怒和抑郁这类精神状态较少。那些锻炼最刻苦的人在大脑反应速度和注意力上也有改善。第二项研究涉及65位患有轻度认知功能障碍的久坐老人,年纪在55至89岁之间,他们进行适度至高强度有氧运动可降低脑脊液中异常蛋白的含量和提高大脑记忆和加速处理中心的血液流动。此类有氧运动似乎能提高注意力、计划和组织能力。最后,一项针对患血管性认知障碍的71名年纪界于56至96岁的老人为期6个月的研究表明,参加有人监护的有氧运动可以提高记忆力和注意力。这些研究结果突出地说明了阿尔茨海默病和其它痴呆症的非药物疗法的潜在价值,并且提醒我们进行研究就应该不动摇地寻找治疗和预防阿尔茨海默病的多种方法。

阿兹海默症协会国际会议简介

阿兹海默症协会国际会议(AAIC)是同类会议中规模最大的,聚集了来自世界各地专注于阿兹海默症及其它痴呆症的领先研究人员。作为阿兹海默症协会研究项目的一部分,该会议旨在提供痴呆症最新相关知识和培养一个充满活力的学院研究社区。

AAIC 2015主页: www.alz.org/aaic/

AAIC 2015新闻室: www.alz.org/aaic/press.asp

阿兹海默症协会简介

阿兹海默症协会是世界领先的从事阿兹海默症护理、支持和研究的自发卫生组织。该协会的使命是通过推动研究来消除阿兹海默症,为所有受到疾病影响的人们提供并加强护理和支持,并通过改善大脑健康状况来降低罹患痴呆症的风险。该协会的愿景是创造一个没有阿兹海默症的世界。详情请访问:alz.org 或致电:800-272-3900。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1946721, encodeId=72281946e21bd, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Oct 20 02:34:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817673, encodeId=9609181e6736e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jan 17 22:34:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816650, encodeId=cfd61816650a4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 28 03:34:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33872, encodeId=d403338e2a6, content=张知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:03:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33790, encodeId=f0a333e90e4, content=希望还有更多新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:44:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470027, encodeId=ba3714e002721, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 29 08:34:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33614, encodeId=5a643361433, content=这基本代表了这个领域的最新的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jul 27 23:51:00 CST 2015, time=2015-07-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1946721, encodeId=72281946e21bd, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Oct 20 02:34:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817673, encodeId=9609181e6736e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jan 17 22:34:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816650, encodeId=cfd61816650a4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 28 03:34:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33872, encodeId=d403338e2a6, content=张知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:03:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33790, encodeId=f0a333e90e4, content=希望还有更多新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:44:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470027, encodeId=ba3714e002721, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 29 08:34:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33614, encodeId=5a643361433, content=这基本代表了这个领域的最新的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jul 27 23:51:00 CST 2015, time=2015-07-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1946721, encodeId=72281946e21bd, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Oct 20 02:34:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817673, encodeId=9609181e6736e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jan 17 22:34:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816650, encodeId=cfd61816650a4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 28 03:34:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33872, encodeId=d403338e2a6, content=张知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:03:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33790, encodeId=f0a333e90e4, content=希望还有更多新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:44:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470027, encodeId=ba3714e002721, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 29 08:34:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33614, encodeId=5a643361433, content=这基本代表了这个领域的最新的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jul 27 23:51:00 CST 2015, time=2015-07-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1946721, encodeId=72281946e21bd, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Oct 20 02:34:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817673, encodeId=9609181e6736e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jan 17 22:34:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816650, encodeId=cfd61816650a4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 28 03:34:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33872, encodeId=d403338e2a6, content=张知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:03:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33790, encodeId=f0a333e90e4, content=希望还有更多新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:44:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470027, encodeId=ba3714e002721, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 29 08:34:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33614, encodeId=5a643361433, content=这基本代表了这个领域的最新的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jul 27 23:51:00 CST 2015, time=2015-07-27, status=1, ipAttribution=)]
    2015-07-30 shenyifeiyang

    张知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1946721, encodeId=72281946e21bd, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Oct 20 02:34:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817673, encodeId=9609181e6736e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jan 17 22:34:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816650, encodeId=cfd61816650a4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 28 03:34:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33872, encodeId=d403338e2a6, content=张知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:03:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33790, encodeId=f0a333e90e4, content=希望还有更多新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:44:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470027, encodeId=ba3714e002721, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 29 08:34:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33614, encodeId=5a643361433, content=这基本代表了这个领域的最新的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jul 27 23:51:00 CST 2015, time=2015-07-27, status=1, ipAttribution=)]
    2015-07-29 快乐晴天

    希望还有更多新进展

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1946721, encodeId=72281946e21bd, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Oct 20 02:34:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817673, encodeId=9609181e6736e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jan 17 22:34:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816650, encodeId=cfd61816650a4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 28 03:34:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33872, encodeId=d403338e2a6, content=张知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:03:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33790, encodeId=f0a333e90e4, content=希望还有更多新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:44:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470027, encodeId=ba3714e002721, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 29 08:34:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33614, encodeId=5a643361433, content=这基本代表了这个领域的最新的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jul 27 23:51:00 CST 2015, time=2015-07-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1946721, encodeId=72281946e21bd, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Tue Oct 20 02:34:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817673, encodeId=9609181e6736e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jan 17 22:34:00 CST 2016, time=2016-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816650, encodeId=cfd61816650a4, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Sat May 28 03:34:00 CST 2016, time=2016-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33872, encodeId=d403338e2a6, content=张知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8681634464, createdName=shenyifeiyang, createdTime=Thu Jul 30 13:03:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33790, encodeId=f0a333e90e4, content=希望还有更多新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150831/IMG55E3D52F183271575.jpg, createdBy=ff291636416, createdName=快乐晴天, createdTime=Wed Jul 29 15:44:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470027, encodeId=ba3714e002721, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jul 29 08:34:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33614, encodeId=5a643361433, content=这基本代表了这个领域的最新的进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Mon Jul 27 23:51:00 CST 2015, time=2015-07-27, status=1, ipAttribution=)]
    2015-07-27 lovetcm

    这基本代表了这个领域的最新的进展

    0

相关资讯

FASEB :Omega-3脂肪酸和抗氧化剂补充剂或可对阿尔兹海默症有疗效

最新一项研究表明,鱼油补充剂和抗氧化剂对治疗阿尔茨海默氏症可能有效。2015年7月发表在《美国实验生物学学会联合会杂志》上的一篇新文章发现,患有轻度临床认知障碍的病人在认知障碍疾病的早期阶段可观察到β-淀粉样蛋白标志出现了间隙,并在神经组织中减少了炎症的发生。尽管在此项实验中研究了12个病人并且历时达4-17个月,但是调查结果显示这种相对经济且充足的补充剂在进一步临床研究中应该继续进行。 “研究

开玩笑!这个女博士三年发了45篇SCI!

博士三年可以完成哪些事情?有的小伙伴觉得发个三篇SCI已经非常不容易了!有的小伙伴觉得能完成毕业的指标就可以~今天,让我们来看看中国海洋大学的一位女博士的三年博士生涯,大伙儿都要加把劲啊! 你如法想象谭梦姗瘦小的身体里蕴藏着多大的力量,三年博士生活,谭梦姗发表了45篇SCI,其中第一作者和共同第一作者12篇,单篇最高影响因子10.11,第一作者累计影响因子52。课题“阿尔茨海默病发病的神

Radiology:成像测试可鉴定老年痴呆标志物

根据发表在《放射学》杂志上一项新的研究结果表示,大脑的蛋白质变性可能是阿尔茨海默病(AD)的早期特定类型标志,包括早发型阿尔兹海默症。 “阿尔茨海默氏症是一种灰质疾病”,医学博士Federica Agosta说,“然而,白质损害中起重要作用的是疾病是如何进展的。” 阿尔兹海默症是一种不可逆转的,缓慢破坏记忆力和思维能力的进行性大脑疾病。这种疾病的特点在整个大脑有异常蛋白质的沉积,并形成淀粉

PLOS MED:抗高血压药物治疗或降低AD风险

 阿尔茨海默病(AD)流行趋势正处于上升的趋势,已经造成了越来越大的社会和经济压力。流行病学研究已经证明了潜在的可以修改的风险因子可以作为靶点来预防AD。这些风险因子包括了2型糖尿病和血糖特征、高血压、肥胖、吸烟、缺少体育锻炼、抑郁、血脂紊乱和较低的受教育程度。据报道,全球范围内有大约三分之一的AD病例是归因于这些风险因子的。考虑到实施大规模的风险因子修改的随机临床试验有着较大的难度,有

Plos Medicine:可控风险因素和阿尔兹海默症的关联

全球存在大约四千万老年痴呆症患者,而且数量还有增加的趋势,据估计到2050年全球将会有1.5亿老年痴呆患者。这些老年患者往往表现为记忆力下降,交流障碍和认知功能障碍。在这些老年痴呆患者中,最常见的是阿尔兹海默症(AD),大约占到60%-70%。研究者们一直在试图寻找AD的成因,尤其是那些可能的可控风险因素,因为通过控制这些因素可能可以降低AD的发病率。流行病学的研究已经发行了几种潜在的风险因素,例

上海交通大学乐卫东团队阿尔茨海默病新发现

最新一期的神经病学权威杂志Alzheimer's & Dementia日前刊登了上海交通大学医学院附属瑞金医院神经病学研究所乐卫东教授课题组研究成果(Alzheimer's & Dementia. 2015 Jun 26. doi: 10.1016)。该杂志由国际阿尔茨海默病及痴呆协会主办,2014年该杂志的影响因子是12.407分。在乐教授的指导下,刘会博士等通过历时四年的时间,